As 2018 draws to a close, I want to end on a hopeful note. In this post I share how the era of immunotherapy, specifically immune-checkpoint-inhibitors, has changed the landscape of community oncology practice, by significantly extending survival rates in stage 4 (metastatic) non-small-cell lung cancer. I want to tell you the story of Joe.…
2 Commentsauthor site